Key TakeawaysNovo Nordisk, maker of weight-loss drugs like Ozempic and Wegovy, reported second-quarter results that fell short of analysts' estimates.Sales of the company's weight-loss drugs helped boost sales and earnings, but not not enough to meet projections.Novo Nordisk lifted its sales estimates, but cut its profit outlook for the full year. Novo Nordisk's (NVO) American depositary receipts (ADRs) slipped in pre-market trading Wednesday morning after rising sales of the company's weight-loss drugs fai ...